鼻内给药 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
| Property | Value | Notes |
|---|---|---|
| 化学类别 | 合成七肽 | ACTH(4-10) 结构类似物 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | 单字母写作 MEHFPGP |
| 分子量 | 约 813.9 Da | 随确切形式和盐型略有变化 |
| 常见同义词 | ACTH(4-10) 类似物 | 俄语文献称 Семакс |
| 开发来源 | 俄罗斯 | 二十世纪八十年代 |
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
=== Psychosis model === Early studies of DET as well as other psychedelics were focused on their presumed psychotomimetic properties. Researchers theorized that abnormal metabolites of endogenous chemicals such as tryptamine, serotonin, and tryptophan could be the explanation for mental disorders such as schizophrenia, or psychosis. DET, along with other synthetic psychedelics, was administered to both patients and healthy volunteers to understand its effects and as a possible biological model for psychosis. With the progression of science and pharmacological understanding, this belief has been dismissed by most researchers.
== Research == A number of agents are currently being investigated in Phase II clinical trials for IPF, including the monoclonal antibodies simtuzumab, tralokinumab, lebrikizumab and FG-3019, a lysophosphatidic acid receptor antagonist (BMS-986020). A Phase II study of STX-100 is also ongoing. These molecules are directed against several growth factors and cytokines that are known to play a role in the proliferation, activation, differentiation or inappropriate survival of fibroblasts. mir-29 microRNA precursor investigations in mice have produced reversal of induced IPF. MRG-201 is currently being tested as-of 2016, but not in IPF patients yet, and no human trials for IPF use have been scheduled as of January 2016. Stem cell therapies for IPF are an area of research. A machine learning algorithm has been proposed that discovers subtle patterns in individual history of medical encounters to reliably estimate the risk of a future IPF diagnosis, up to four years before current medical practice. The algorithm outputs a score (ZCoR) using medical history on file with no new tests, and might be deployable as a universal IPF screening tool in primary care. ZCoR has been trained and validated on nearly 3 million patients across multiple databases, achieving high predictive performance in out-of-sample data (positive likelihood ratio > 30 with 99% specificity).
The Spartanburg Pellagra Hospital in Spartanburg, South Carolina, was the first facility in the United States dedicated to discovering the cause of pellagra. It was established in 1914 with a special Congressional appropriation to the U.S. Public Health Service and set up primarily for research. In 1915, Dr. Joseph Goldberger, assigned to study pellagra by the surgeon general of the United States, showed it was linked to diet by observing the outbreaks of pellagra in orphanages and mental hospitals. Goldberger noted that children between the ages of 6 and 12 (but not older or younger children at the orphanages) and patients at the mental hospitals (but not doctors or nurses) were the ones who seemed most susceptible to pellagra. Goldberger theorized that a lack of meat, milk, eggs, and legumes made those particular populations susceptible to pellagra. By modifying the diet served in these institutions with "a marked increase in the fresh animal and the leguminous protein foods," Goldberger was able to show that pellagra could be prevented. By 1926, Goldberger established that a diet that included these foods, or a small amount of brewer's yeast, prevented pellagra. Goldberger experimented on 11 prisoners (one was dismissed because of prostatitis). Before the experiment, the prisoners were eating the prison fare fed to all inmates at Rankin Prison Farm in Mississippi. Goldberger started feeding them a restricted diet of grits, syrup, mush, biscuits, cabbage, sweet potatoes, rice, collards, and coffee with sugar (no milk).
Sources: en.wikipedia.org
== Use in diagnostic tests == Fecal elastase is an enzyme originally thought to be pancreatic elastase 1 (CELA1), but this was discovered to be an error, and it is actually likely be CELA3B. Fecal elastase is not degraded in intestinal transit, so that its concentration in feces reflects exocrine pancreatic function. In inflammation of the pancreas, fecal elastase is released into the bloodstream. Thus the quantification of fecal elastase in serum allows diagnosis or exclusion of acute pancreatitis. Main indications:
== Boards of Directors == Bowman has served on the boards of directors of a number of companies in the areas of innovative technologies and the life sciences in addition to Dionex. From 1985 to 2007, Bowman served as a director of Molecular Devices Corporation, a supplier of bioanalytical measurement instruments. In 2006, he was appointed lead director of the board of Cell BioSciences, a privately held company engaged in protein research in the emerging area of nanoproteomics. He was appointed to the board of Solexa, Inc. in 2006. Solexa, which developed genome sequencing technology, was acquired in 2007 by Illumina, Inc., on whose board of directors Bowman now serves. Illumina develops tools for DNA, RNA, and protein analysis. A. Blaine Bowman joined Altera Corporation's board of directors as of July 30, 2012. Altera develops programmable logic devices.
Varying concentrations of Asparagopsis taxiformis were mixed with Rhodes grass and examined using standardised in vitro culture methods. Five dosages were tested ranging from 0.5% to 10% of dietary composition. The optimum concentration was determined to be 2%, as it virtually eliminated methane production and reduced the volume of total gases produced by 30% without affecting fermentation efficiency. Dosages under 5% had no effect on volatile fatty acid concentrations, which is the primary source of energy resulting from digestion. In 2016, live tests were performed on sheep at the CSIRO Centre for Environment and Life Sciences in Floreat, Western Australia. 29 merino sheep were fed one of five dosage levels (0%, 0.5%, 1%, 2% or 3% dietary intake) and monitored over a 72-day feeding period. In dosages of 2%, methane emission reductions of up to 85% were recorded when compared to control sheep. The sheep given dosages of 0.5% recorded at least a 50% reduction in methane emissions. No evidence of microbial adaptation occurred over the 72 days of testing and methane was continually and consistently mitigated. Tissue examination showed no adverse effects on the overall health of the sheep. In 2017, live tests over 90 days were performed on cattle at the CSIRO Lansdown facility in Queensland. 28 Brahman-Angus steers were separated into four groups and given varying dosages of dried Asparagopsis in a simulated feedlot. Concentration levels for each group were 0% (control), 0.5% (low), 1% (medium) and 2% (high) intake of Asparagopsis.
Sources: en.wikipedia.org
不是。Semax 是完全人工合成的七肽，自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10)，但序列经过了替换和延长。
Semax 被描述为 ACTH(4-10) 的结构类似物，两者共享部分序列特征。它保留了该片段的部分神经相关活性方向，但去除了完整片段带来的激素释放效应。二者并非同一物质，也不能互相替代。
加入的 Pro-Gly-Pro 三肽被普遍认为能提升分子对蛋白水解酶的稳定性。这种设计让短肽在体内维持时间更长。具体延长的程度以及不同组织中是否一致，文献中仍存在不同报告。
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.